The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The study will run across 18 sites and enroll roughly 200 patients over 24 months
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The plant is expected to enhance regional supply capabilities
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Subscribe To Our Newsletter & Stay Updated
